SVF
Level A· Stronger Clinical EvidenceSystematic Review

The efficacy of adipose-derived stem cell therapy for complex perianal fistulas in Crohn's disease patients: A systematic review.

Aldakhil M., Albarrak RI., Alomar JA., Alnasr LI., Alassaf RM., Alhumaid NK.

Systematic Review with a reported sample of 19 on Chronic Inflammation, Autoimmune Research, published in Surg Open Sci (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Surg Open Sci (2026)
Country
United States
Reported sample size
19
PMID
41509007
DOI
10.1016/j.sopen.2025.11.002

Abstract (original English)

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that often leads to the development of complex perianal fistulas, significantly impairing patients' quality of life. Conventional medical and surgical treatments offer limited long-term efficacy, with high recurrence rates and associated complications. Adipose-derived stem cell therapy (ADSCT) has emerged as a promising regenerative therapy due to its anti-inflammatory and tissue-regenerative properties. However, discrepancies in clinical outcomes across studies warrant a systematic evaluation of its efficacy and safety. This systematic review aims to critically assess the efficacy, safety, and recurrence rates of ADSCT for complex perianal fistulas in Crohn's disease patients, summarizing data from randomized controlled trials and observational studies. This review included 19 studies published between 2009 and 2024 involving Crohn's disease patients treated with either autologous or allogeneic ADSCT. Extracted data included patient demographics, fistula characteristics, treatment protocols, and clinical outcomes such as fistula closure, partial healing, time to healing, recurrence, and adverse events. Study selection followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and is illustrated in a PRISMA flow diagram. Risk of bias was assessed using the Cochrane Risk o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Systemic / IVChronic InflammationAutoimmune Research
View on PubMedDOI

Related research